In the last trading session, 1.32 million Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) shares changed hands as the company’s beta touched 1.23. With the company’s per share price at $8.62 changed hands at -$0.01 or -0.12% during last session, the market valuation stood at $1.16B. AUPH’s last price was a discount, traded about -23.78% off its 52-week high of $10.67. The share price had its 52-week low at $5.20, which suggests the last value was 39.68% up since then. When we look at Aurinia Pharmaceuticals Inc’s average trading volume, we note the 10-day average is 2.17 million shares, with the 3-month average coming to 1.50 million.
Analysts gave the Aurinia Pharmaceuticals Inc (AUPH) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.50. If we narrow down to specifics, the data shows that 0 out of 3 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 1 recommended AUPH as a Hold, 2 felt it is a Buy and 0 rated the stock as Underweight.
Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) trade information
Instantly AUPH was in red as seen at the end of in last trading. With action -4.65%, the performance over the past five days has been red. The company’s shares are showing year-to-date upside of 47.60%, with the 5-day performance at -4.65% in the red. However, in the 30-day time frame, Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) is 8.84% up. Looking at the short shares, we see there were 10.53 million shares sold at short interest cover period of 8.4 days.
The consensus price target for the stock as assigned by Wall Street analysts is 12, meaning bulls need an upside of 28.17% from its current market value. According to analyst projections, AUPH’s forecast low is 6 with 13 as the target high. To hit the forecast high, the stock’s price needs a -50.81% plunge from its current level, while the stock would need to tank 30.39% for it to hit the projected low.
Aurinia Pharmaceuticals Inc (NASDAQ:AUPH)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 9.07% of Aurinia Pharmaceuticals Inc shares while 47.22% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 51.93%. There are 47.22% institutions holding the Aurinia Pharmaceuticals Inc stock share, with ARMISTICE CAPITAL, LLC the top institutional holder. As of 2024-06-30, the company held 7.7696% of the shares, roughly 11.14 million AUPH shares worth $63.59 million.
BLACKROCK INC. holds the second largest percentage of outstanding shares, with 6.4692% or 9.27 million shares worth $52.94 million as of 2024-06-30.
Among Mutual Funds, the top two as of May 31, 2025 were iShares Trust-iShares Russell 2000 ETF and Fidelity Salem Street Trust-Fidelity Small Cap Index Fund. With 3.35 shares estimated at $28.92 million under it, the former controlled 2.48% of total outstanding shares. On the other hand, Fidelity Salem Street Trust-Fidelity Small Cap Index Fund held about 1.01% of the shares, roughly 1.36 shares worth around $11.72 million.
